In addition, most cytokines are associated with higher cardiovascular risk and represent independent cardiovascular risk factors [16,17], which is a concept that was more recently explored for pharmacological targeting, e.g., within the “CANTOS trial” using “Canakinumab”, a monocloncal antibody against interleukin-1β in patients with previous myocardial infarction and high C-reactive protein (CRP) levels [18] and many other published or ongoing studies (reviewed in [19]). The gene discussed is CRP; the disease is myocardial infarction.